Replies to post #213808 on Biotech Values

[DewDiligence]

ENTA—...wrt to NASH, do the data/results to date for edp-305 give you enough of a clear understanding of its MOA?

No, they do not. To date, the only reported data for EDP-305 are preclinical. Moreover, NASH—unlike HCV—is a multifaceted disease where the MoAs of the various drug classes being tested are poorly understood by comparison to the DAAs for HCV.

Regarding FXR agonists specifically, I don't consider ICPT's results in the phase-2 FLINT study to be full-fledged validation of this MoA for treating NASH.

In short, the investing theme described in my prior post doesn’t apply to NASH.